infections are detected in the absence of blood transfusions, HGV may be another marker of nosocomial Background. The prevalence, incidence, risk factors, and clinical impact of infection by the recently disco-viral transmission. Once acquired, the infection persists for many years in HD patients. vered hepatitis G virus ( HGV ) in haemodialysed ( HD) patients, are poorly defined. Methods. All 119 HD patients from two Belgian units Key words: Belgium; coinfection; haemodialysis; nonselected for their diÂerent hepatitis C virus ( HCV ) A-E hepatitis; viral hepatitis prevalences (A: 19.2%, B: 3.4%) were tested for the presence of HGV-RNA, using the reverse transcriptase polymerase chain reaction ( RT-PCR) and primers from the 5∞-NC and NS 5a genome regions. The results Introduction transmission routes seem similar to those of the hepaResults. HGV-RNA was detected with both sets of titis C virus (HCV ).Few data are available on HGV primers in 11/78 patients (14.1%) from centre A and infection in haemodialysis (HD) [4][5][6]. We therefore 8/41 patients (19.5%) from centre B, for an average studied the prevalence, risk factors, incidence, and prevalence of 16%. One patient was indeterminate clinical relevance of HGV infection in all HD patients ( positive with one set of primers). The presence of from two Belgian units with diÂerent HCV prevalences HGV-RNA correlated neither with time on HD (P= (19.2% and 3.4%, respectively). 0.18), nor with the number of transfusions on HD (P=0.14). It was associated with the presence of anti-HCV antibodies in centre A (P<0.01) but not B Materials and methods (P>0.5). Twenty-seven initially negative (-) patients ( A: n=18; B: n=9 ) were retested: two became positive Patients and samples (+) both in the absence of transfusions for years, giving a yearly incidence of 1.7%. The 13 initially One-hundred and nineteen patients on maintenance HD in HGV-RNA (+) patients remained so over time (33 two centres, one in Brussels (centre A) and one in Baconfoy patient-years). The presence of HGV-RNA alone does (centre B) situated in the Ardennes, were tested. All sera had been processed individually and kept frozen. In centre A sera not increase significantly the ALT level, in contrast to of 1991 from 78 patients were investigated and the 21 patients the strong influence of HCV.
from the 5∞-NC and NS 5a genome regions. The results Introduction of anti-HCV antibodies and alanine aminotransferase levels (ALT) at the time of RT-PCR, number of The recently discovered GB virus C (GBV-C ) [1] and transfusions from the onset of HD, and time on HD hepatitis G virus (HGV ) [2] are strains of the same were retrieved from the medical charts. Forty patients blood-borne virus [3 ] (further called HGV ), whose were retested by RT-PCR 3-64 months later.
transmission routes seem similar to those of the hepaResults. HGV-RNA was detected with both sets of titis C virus (HCV ) .Few data are available on HGV primers in 11/78 patients (14.1%) from centre A and infection in haemodialysis (HD) [4] [5] [6] . We therefore 8/41 patients (19.5%) from centre B, for an average studied the prevalence, risk factors, incidence, and prevalence of 16%. One patient was indeterminate clinical relevance of HGV infection in all HD patients ( positive with one set of primers). The presence of from two Belgian units with diÂerent HCV prevalences HGV-RNA correlated neither with time on HD (P= (19.2% and 3.4%, respectively). 0.18), nor with the number of transfusions on HD (P=0.14). It was associated with the presence of anti-HCV antibodies in centre A (P<0.01) but not B Materials and methods (P>0.5). Twenty-seven initially negative (-) patients ( A: n=18; B: n=9 ) were retested: two became positive Patients and samples (+) both in the absence of transfusions for years, giving a yearly incidence of 1.7%. The 13 initially One-hundred and nineteen patients on maintenance HD in HGV-RNA (+) patients remained so over time (33 two centres, one in Brussels (centre A) and one in Baconfoy patient-years). The presence of HGV-RNA alone does (centre B) situated in the Ardennes, were tested. All sera had been processed individually and kept frozen. In centre A sera not increase significantly the ALT level, in contrast to of 1991 from 78 patients were investigated and the 21 patients the strong influence of HCV.
still on HD in A in 1996 were re-evaluated 63 months later.
Conclusion. The prevalence and yearly incidence of
In centre B sera drawn in 1994 from 29 patients were tested HGV infection are 16% and 1.7%, respectively, in our and the nine patients still on HD in 1996 were retested 27 HD patients. Neither the number of transfusions on months later together with 12 new patients (see Table 1 ). HD nor the time on HD are significant risk factors. When a HGV positive sample was found, all available earlier Although mixed HCV/HGV infections indicate and later samples of the patient were tested to confirm our common risks, the prevalence of HCV in a particular results and to define whenever possible the duration of setting does not predict prevalence of HGV. As new HGV carriage.
Data on transfusions while on haemodialysis, time on HD and alanine aminotransferase (ALT ) levels at the time of aIndeterminate: positive with one primer set and negative with the other. bThe total indicates the final status of the patients. The total number of patients is not the sum of the columns: a number of them were tested at diÂerent time points and some negatives converted to positive. Centre A is in Brussels, centre B in Baconfoy (Ardennes).
factor was introduced in ALT values from centre B for third generation (Ortho Diagnostic Systems, Neckargemü nd, Germany). Repeatedly reactive samples were further concomparability.
firmed by an immunoblot (RIBA HCV 3.0 SIA, Chiron Corp., Emeryville, USA) and/or by the detection of HCV-
Viral RNA was detected by reverse transcriptase polymerase chain reaction (RT-PCR). RNA was extracted from 50 ml Statistics of serum using the guanidinium isothiocyanate-phenolchloroform method [7 ] . The sequences of oligonucleotide Quantitative values are expressed as mean±SD. primers and probes used in the detection of HGVMann-Whitney U test, unpaired t test, x2 and Fisher's exact RNA were those described by Schlueter et al. [8] . They test were calculated where needed. P values <0.05 were are located in the putative 5∞ non-coding (5∞-NCR) considered as significant. Confidence intervals on proporand NS5a regions of the viral genome (5∞-NCR primer 1:
tions, diÂerences and odds ratios were calculated with the 5∞-CGGCCAAAAGGTGGTGGATG-3∞, primer 2: 5∞-Confidence Interval Analysis software, version 1.2 (BMJ, CGACGAGCCTGACGTCGGG-3∞, probe: London) 5∞-GGTAGCCACTATAGGTGGG-3∞; NS5a primer 1: 5∞-CTCTTTGTGGTAGTAGCCGAGAGAT-3∞, primer 2: 5∞-CGAATGAGTCAGAGGACGGGGTAT-3∞, probe: 5∞-GTTACTGAGAGCAGCTCAGAT-3∞). The reverse tran- There were 72 males (60.5%) and 47 females (39.5%).
transcriptase (Gibco BRL). The cDNA was amplified in a The mean age of the patients was 58.3 years (median final volume of 100 ml containing 10mM Tris-HCl, 1.5 mM MgCl 2 , 50 mM KCl, gelatine 0.1%, 0.1 mM of each dNTP, age: 61 years; range: 21-85 years). They had been on 2 U Taq DNA polymerase (Perkin Elmer) and 50 pM of dialysis for a mean of 49 months (median: 27 months; specific primers either in the 5∞-NCR or NS5a region. Forty range: 1 month-24 years). While on HD the patients cycles were performed ( 1 min at 94°C, 1 min at 55°C, and 2 received a mean of 12.9 units of blood (median: 4 min at 72°C ) with a final extension of 5 min at 72°C. Positive units; range: 0-154 units).
and negative controls were run with each experiment. Falsepositive results were avoided by strict application of contamination prevention measures. The amplification products
Prevalences of HGV-RNA and HCV antibodies
were visualized by electrophoresis in agarose gel and ethidium bromide staining. The specificity of the amplification prod-The results are summarized in Table 1 . In centre A the ucts was confirmed by Southern hybridization with each 1991 prevalences of HGV and HCV were 14.1% (95% internal specific probe labelled with digoxigenin using the C.I. the NS5a region and negative for the 5∞-NCR on two samples taken 36 months apart) was excluded from further analysis. The HGV prevalences did not diÂer HCV markers significantly between the two centres, while the HCV prevalence was significantly lower in centre B than in All patients had been tested previously at several points of time for anti-HCV antibodies with ELISAs of second and centre A.
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Annual incidence of HGV infection whom the time of infection could be traced, two did not receive any transfusion during the preceding years. Out of 95 patients initially found negative for HGV-RNA, 27 could be retested in 1996 (18 from centre A and nine from centre B). Two infections, both in centre A, before September 1993, were observed during a Discussion total observation period of 114.7 patient-years, giving a yearly incidence of 1.7% (95% C.I.: 0.2-6.1). If we In this study, we found a 16% prevalence of HGV limit our analysis to centre A the incidence is 6.7% viraemia in Belgian haemodialysis patients. This figure ( 95% C.I.: 0.8-22.1) per year before September 1993 is similar to that in Italian HD patients ( 19%) [5] , but and 0% (95% C.I.: 0-5.6) thereafter (not significant). very diÂerent from the 3% found in Japanese patients [4] and 55% in French patients [6 ] . The prevalence Evolution in HGV-RNA (+) patients figures in our study might underestimate the actual number of those ever infected by HGV, because we Retrospective or prospective follow-up sera were availonly detected current viraemia. However, the almost able from 13 of 21 patients found positive during the uniform long persistence of HGV-RNA observed in investigation. These 13 patients were observed from longitudinal studies, both in Belgian (this study) and their first positive sample for a total of 33 patientJapanese HD patients [4 ] , suggests that a large proporyears ( 3-64 months). HGV-RNA was detected in all tion of the ever infected patients were detected by at last follow-up.
RT-PCR. We cannot exclude that the RT-PCR method misses a number of viraemic patients, especiClinical relevance ally as HGV exhibits significant genomic variability.
To minimize the chances of missing variants, we ampliWhen comparing mean alanine aminotransferase fied the genome in two regions (in contrast to Masuko ( ALT ) levels of 118 patients at the time of their first et al.
[4 ] who found a much lower prevalence) and test for HGV ( Table 2) , no diÂerences are found found concordant results in all cases except one: thus between HGV positives and negatives when they are both primer pairs have comparable sensitivities in our HCV negative. HCV positive patients have higher patients. mean ALT values than HCV negatives. This is most Interestingly, the long-term evolution of HGV infecmarked in those with a mixed infection with HCV and tion may well be diÂerent in various high-risk groups. HGV, but this trend was not statistically significant.
Indeed the lower prevalence of HGV than HCV infecThe monthly ALT levels remained stable and normal tions in haemophiliacs has been tentatively attributed throughout the observation period in all five cases with to a shorter duration of HGV than HCV viraemia recent onset of HGV infection.
[10]. In line with this finding suggesting the potential In HGV-RNA (+) patients, no mention was found of clearance of HGV viraemia in immunocompetent of a particular disease or haematological abnormality patients, the presence of HGV-RNA in survivors of on scanning their files.
haematological malignancy was significantly associated with previous bone marrow transplantation (taken as Risk factors an index of more profound immunosuppression) but not with exposure to a higher number of blood donors In centre A, with a high prevalence of hepatitis C, the presence of anti-HCV antibodies is associated with an [11]. More recently Tacke et al. [12] have demonstrated that a humoral immune response to the HGV envelope increased risk of HGV infection (O.R.=4.3; 95% C.I. : 1.12-16.4). No diÂerences were found between HGV may develop in a substantial proportion of intravenous drug abusers or post-transfusional cases and be associpositives and negatives in the number of transfusions since initiation of haemodialysis (P=0.14) or in the ated with loss of detectable HGV viraemia. If confirmed, this diÂerential risk of long-term persistence of time on HD (P=0.18). Among the five patients in 
